| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Humanigen Inc (NASDAQ: HGEN)
HGEN Technical Analysis
5
| As on 9th Jun 2023 HGEN STOCK Price closed @ 0.15 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.61 & Strong Sell for SHORT-TERM with Stoploss of 2.69 we also expect STOCK to react on Following IMPORTANT LEVELS. |
HGENSTOCK Price
| Open | 0.14 | Change | Price | % |
| High | 0.15 | 1 Day | 0.01 | 7.14 |
| Low | 0.14 | 1 Week | -0.01 | -6.25 |
| Close | 0.15 | 1 Month | -0.01 | -6.25 |
| Volume | 2294101 | 1 Year | -3.63 | -96.03 |
| 52 Week High 4.05 | 52 Week Low 0.09 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| HGEN Daily Charts |
HGEN Intraday Charts |
Whats New @ Bazaartrend |
HGEN Free Analysis |
|
|
HGEN Important Levels Intraday
| RESISTANCE | 0.17 |
| RESISTANCE | 0.16 |
| RESISTANCE | 0.16 |
| RESISTANCE | 0.16 |
| SUPPORT | 0.14 |
| SUPPORT | 0.14 |
| SUPPORT | 0.14 |
| SUPPORT | 0.13 |
HGEN Forecast May 2024
| 4th UP Forecast | 3.14 |
| 3rd UP Forecast | 2.18 |
| 2nd UP Forecast | 1.59 |
| 1st UP Forecast | 0.99 |
| 1st DOWN Forecast | -0.69 |
| 2nd DOWN Forecast | -1.29 |
| 3rd DOWN Forecast | -1.88 |
| 4th DOWN Forecast | -2.84 |
HGEN Weekly Forecast
| 4th UP Forecast | 1.38 |
| 3rd UP Forecast | 0.99 |
| 2nd UP Forecast | 0.74 |
| 1st UP Forecast | 0.50 |
| 1st DOWN Forecast | -0.20 |
| 2nd DOWN Forecast | -0.44 |
| 3rd DOWN Forecast | -0.69 |
| 4th DOWN Forecast | -1.08 |
HGEN Forecast2024
| 4th UP Forecast | 8.07 |
| 3rd UP Forecast | 5.53 |
| 2nd UP Forecast | 3.96 |
| 1st UP Forecast | 2.39 |
| 1st DOWN Forecast | -2.09 |
| 2nd DOWN Forecast | -3.66 |
| 3rd DOWN Forecast | -5.23 |
| 4th DOWN Forecast | -7.77 |
Humanigen Inc ( NASDAQ USA Symbol : HGEN )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
HGEN Business Profile
Humanigen, Inc., a clinical stage biopharmaceutical company, develops a portfolio of immuno-oncology and immunology monoclonal antibodies in the United States. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes human granulocyte-macrophage colony-stimulating factor, which is in Phase III clinical trial for the treatment of cytokine storm associated with COVID-19; and Phase Ib/II clinical trial as a sequenced therapy in combination with CD19 targeted chimeric antigen receptor T-cell therapies to treat patients with relapsed or refractory B-cell lymphoma, as well as that has completed Phase I clinical trial in patients with chronic myelomonocytic leukemia. It also develops Ifabotuzumab, a humaneered monoclonal antibody that targets EphA3 receptor, which has completed the Phase I dose escalation portion of a Phase I/II clinical trial in multiple hematologic malignancies; and HGEN005, an anti-EMR1 monoclonal antibody, which is in pre-clinical stage for the treatment of eosinophilic disorders. Humanigen, Inc. has a clinical collaboration agreement with Kite Pharma, Inc. to conduct a multi-center Phase Ib/II study of Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma; and a cooperative research and development agreement with the Department of Defense to assist in the development of lenzilumab in advance of a potential emergency use authorization for COVID-19. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was incorporated in 2000 and is based in Burlingame, California. Address: 533 Airport Boulevard, Burlingame, CA, United States, 94005
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service